DGS Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.2M Buy
3,475
+70
+2% +$71K 0.52% 32
2025
Q4
$3.66M Buy
3,405
+158
+5% +$151K 0.63% 20
2025
Q3
$2.48M Buy
3,247
+25
+0.8% +$18.6K 0.45% 35
2025
Q2
$2.51M Sell
3,222
-27
-0.8% -$21K 0.52% 30
2025
Q1
$2.68M Sell
3,249
-1,887
-37% -$1.57M 0.71% 24
2024
Q4
$3.96M Sell
5,136
-103
-2% -$85.3K 0.99% 15
2024
Q3
$4.64M Buy
5,239
+350
+7% +$315K 1.26% 12
2024
Q2
$4.43M Buy
4,889
+2,314
+90% +$1.85M 1.24% 12
2024
Q1
$2M Buy
2,575
+648
+34% +$461K 0.57% 24
2023
Q4
$1.12M Sell
1,927
-11
-0.6% -$6.42K 0.43% 37
2023
Q3
$1.04M Buy
1,938
+236
+14% +$122K 0.51% 41
2023
Q2
$798K Buy
1,702
+180
+12% +$75.5K 0.4% 49
2023
Q1
$523K Sell
1,522
-37
-2% -$12.5K 0.29% 79
2022
Q4
$570K Buy
1,559
+116
+8% +$41.1K 0.37% 58
2022
Q3
$466K Buy
1,443
+108
+8% +$34.2K 0.31% 61
2022
Q2
$433K Buy
1,335
+43
+3% +$12.9K 0.35% 62
2022
Q1
$370K Buy
1,292
+46
+4% +$11.8K 0.23% 97
2021
Q4
$344K Buy
+1,246
New +$316K 0.21% 84

Other funds holding LLY

DGS Capital Management's LLY Position: Q1 2026 in Review

DGS Capital Management increased its Eli Lilly (LLY) stake by 2.1% in Q1 2026, buying an estimated $71K and bringing the position to 3,475 shares worth $3.2M. The position accounts for 0.52% of the portfolio, ranked #32.

DGS Capital Management first reported a position in LLY in Q4 2021 and has held it in 18 quarters since. The position peaked at $4.64M in Q3 2024. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • DGS Capital Management held 3,475 shares of Eli Lilly worth $3.2M as of Q1 2026.
  • DGS Capital Management bought 70 Eli Lilly shares in Q1 2026, an estimated $71K.
  • Eli Lilly made up 0.52% of DGS Capital Management's portfolio in Q1 2026, its #32 holding.
  • DGS Capital Management first reported a position in Eli Lilly in Q4 2021 and has held it in 18 quarters since.
  • DGS Capital Management's Eli Lilly position peaked at $4.64M in Q3 2024.
  • 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on DGS Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.